STAT3-IN-54
STAT3-IN-54 is a STAT3 inhibitor. STAT3-IN-54 induces Apoptosis and G0/G1 cell cycle arrest. STAT3-IN-54 exhibits selective anticancer activity against non-small cell lung cancer cells. STAT3-IN-54 can be used for research on non-small cell lung cancer.
For research use only. We do not sell to patients.
- Formula: C17H10BrF2N3O2S
- Molecular Weight:438.25
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
STAT3 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
20.13 μM
|
Cytotoxicity against human A549 lung adenocarcinoma cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay.
Cytotoxicity against human A549 lung adenocarcinoma cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay.
|
42612271 |
| L929 | IC50 |
>500 μM
|
Cytotoxicity against mouse L929 embryonic fibroblast cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay.
Cytotoxicity against mouse L929 embryonic fibroblast cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay.
|
42612271 |
| A549 | IC50 |
2.04 μM
|
Inhibition of STAT3 (Tyr705) in human A549 lung adenocarcinoma cells incubated for 24 hrs by in-cell ELISA assay.
Inhibition of STAT3 (Tyr705) in human A549 lung adenocarcinoma cells incubated for 24 hrs by in-cell ELISA assay.
|
42612271 |
In Vitro
STAT3-IN-54 (Compound 2r) (24 h) exhibits selective cytotoxicity against A549 lung adenocarcinoma cells with an IC50 of 20.13 μM, while showing no cytotoxicity against L929 mouse embryonic fibroblasts at the tested concentrations[1].
STAT3-IN-54 (20.13 μM; 24 h) induces early and late apoptosis in A549 lung adenocarcinoma cells[1].
STAT3-IN-54 (20.13 μM; 24 h) induces cell cycle arrest at the G0/G1 phase in A549 lung adenocarcinoma cells[1].
STAT3-IN-54 (24 h) is a potent STAT3 inhibitor with an IC50 of 2.04 μM in A549 lung adenocarcinoma cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:A549, L929
-
Concentration:Various concentrations
-
Incubation Time:24 h
-
Result:Exerted cytotoxicity against A549 cells with an IC50 of 20.13 μM.
Exhibited an IC50 of >500 μM against L929 cells.
Achieved a selectivity index of >24.84.
-
Cell Line:A549
-
Concentration:IC50 concentration
-
Incubation Time:24 h
-
Result:Induced early apoptosis in 12.95% of A549 cells.
Induced late apoptosis in 6.04% of A549 cells.
Induced total apoptosis of 18.99%.
Induced greater total apoptosis than erlotinib and GSK690693.
-
Cell Line:A549
-
Concentration:IC50 concentration
-
Incubation Time:24 h
-
Result:Induced a cell cycle distribution with 65.84% in G0/G1 phase, 21.01% in S phase, and 5.68% in G2/M phase.
Chemical Information
-
Molecular Weight 438.25
-
Formula C17H10BrF2N3O2S
-
SMILES
FC1=CC=C(C2=CSC(N/N=C/C3=C(Br)C=C(OCO4)C4=C3)=N2)C(F)=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)